Daron Evans Buys 10,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock

Rezolute, Inc. (NASDAQ:RZLT) CFO Daron Evans acquired 10,000 shares of the company’s stock in a transaction dated Wednesday, March 26th. The stock was acquired at an average cost of $2.89 per share, with a total value of $28,900.00. Following the transaction, the chief financial officer now directly owns 237,900 shares of the company’s stock, valued at approximately $687,531. This represents a 4.39 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Rezolute Stock Up 0.3 %

Shares of NASDAQ RZLT opened at $2.93 on Friday. The business has a 50 day moving average price of $4.26 and a two-hundred day moving average price of $4.75. Rezolute, Inc. has a fifty-two week low of $2.22 and a fifty-two week high of $6.19. The firm has a market cap of $177.37 million, a PE ratio of -2.40 and a beta of 0.95.

Rezolute (NASDAQ:RZLT) last issued its quarterly earnings results on Wednesday, February 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.11. On average, analysts anticipate that Rezolute, Inc. will post -0.93 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts recently issued reports on RZLT shares. HC Wainwright reiterated a “buy” rating and issued a $14.00 price target on shares of Rezolute in a report on Thursday, February 13th. Craig Hallum upgraded Rezolute to a “strong-buy” rating in a research note on Tuesday, February 4th. JMP Securities boosted their price target on Rezolute from $8.00 to $9.00 and gave the stock a “market outperform” rating in a research report on Thursday, February 13th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Rezolute in a research report on Monday, February 10th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Rezolute has a consensus rating of “Buy” and a consensus price target of $24.38.

Institutional Investors Weigh In On Rezolute

Institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. bought a new stake in Rezolute in the third quarter valued at about $42,000. Alpine Global Management LLC bought a new stake in shares of Rezolute in the 4th quarter valued at approximately $54,000. MML Investors Services LLC bought a new stake in shares of Rezolute in the 3rd quarter valued at approximately $57,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Rezolute during the 3rd quarter valued at approximately $65,000. Finally, Charles Schwab Investment Management Inc. lifted its stake in Rezolute by 65.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 22,757 shares of the company’s stock worth $112,000 after purchasing an additional 9,000 shares during the last quarter. Institutional investors and hedge funds own 82.97% of the company’s stock.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.